Defense Date


Document Type


Degree Name

Master of Science in Dentistry



First Advisor

Parthasarathy A. Madurantakam, D.D.S., M.D.S., Ph.D.

Second Advisor

Da Huang Ph.D.

Third Advisor

Hu Yang Ph.D.

Fourth Advisor

Thomas C. Waldrop, D.D.S., M.S.


Purpose: Prescription of a complete course of oral antibiotics following bone grafting procedures is a common clinical practice in surgical periodontics. Prophylactic administration of antibiotics reduces the risk of surgical site infection and systemic administration is preferred over local delivery because of short duration of action in the latter circumstance. The goal of this study is to demonstrate the ability of dendrimer hydrogels (DH) to prolong the release kinetics of antibiotics in-vitro. A secondary goal will be to analyze the effect of different particulate bone allografts on the release kinetics of the antibiotic.

Methods: Dendrimer hydrogels (DH) were synthesized from polyamidoamine (PAMAM) G5 and polyethylene glycol diacrylate (PEG-DA) to contain Cefazolin, a first-generation cephalosporin antibiotic, for these in-vitro experiments. Two different types of allogeneic bone grafts (demineralized freeze-dried or freeze-dried) along with a negative control (no bone graft) were used to study the effects of bone graft on the release kinetics of cefazolin. Samples were bathed in PBS and incubated at 37o Celsius while 1mL aliquots were taken at time points 1hr, 2hrs, 3hrs, 4hrs, 5hrs, 6hrs, 12hrs, 24hrs, 48hrs, 72hrs. Aliquots were analyzed using HPLC and a standard curve was used to determine the concentration of cefazolin in each sample.

Results: The estimated maximum concentration of cefazolin in samples containing DH was 36.97mcg/mL (95% CI: 34.58-39.36) with 50% released in 4.17 hours (95%: 3.26-5.07) and an estimated growth rate of 0.27 (95% CI: 0.17-0.37). For samples without DH, estimated maximum concentration of cefazolin was 167.4mcg/mL (95% CI: 160.4-174.4) with 50% released in 2.36 hours (95% CI: 2.05-2.67) and an estimated growth rate of 0.70 (95% CI: 0.54-0.87). Bone grafts did not significantly affect the release of cefazolin in this experiment.

Conclusion: DH is a promising platform for long-term release of cefazolin in-vitro.


© The Author

Is Part Of

VCU University Archives

Is Part Of

VCU Theses and Dissertations

Date of Submission